Cargando…
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large r...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750240/ https://www.ncbi.nlm.nih.gov/pubmed/26867536 http://dx.doi.org/10.1186/s12884-016-0821-3 |
_version_ | 1782415402188406784 |
---|---|
author | Moodley, Theron Moodley, Dhayendre Sebitloane, Motshedisi Maharaj, Niren Sartorius, Benn |
author_facet | Moodley, Theron Moodley, Dhayendre Sebitloane, Motshedisi Maharaj, Niren Sartorius, Benn |
author_sort | Moodley, Theron |
collection | PubMed |
description | BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large regional hospital in South Africa during July-December 2011 and January-June 2014 with an aim to determine an association between pregnancy outcomes and the ARV treatment guidelines implemented during those specific periods. During 2011, women received either Zidovudine/sd Nevirapine or Stavudine/Lamivudine/Nevirapine if CD4+ count was < 350 cells/ml. During 2014, all HIV positive pregnant women were eligible for a fixed dose combination (FDC) of triple ARVs (Tenofovir/Emtracitabine/Efavirenz). RESULTS: In 2011, 622 (35.9 %) of 1732 HIV positive pregnant women received triple antiretrovirals (D4T/3TC/NVP) and in 2014, 2104 (94.8 %) of 2219 HIV positive pregnant women received the fixed dose combination (TDF/FTC/EFV). We observed a reduction in the proportion of unregistered pregnancies, caesarean delivery rate, still birth rate, very low birth weight rate, and very premature delivery rate in 2014. In a bivariate analysis of all 9,847 deliveries, unregistered pregnancies (2.2 %) and HIV infection (37.8 %) remained significant risk factors for SB(OR 6.36 and 1.43 respectively), PTD(OR 4.23 and 1.26 respectively),LBW (OR 4.07 and 1.26 respectively) and SGA(OR 2.17 and 1.151 respectively). In a multivariable analysis of HIV positive women only, having received AZT/NVP or D4T/3TC/NVP or EFV/TDF/FTC as opposed to not receiving any ARV was significantly associated with reduced odds of a SB (OR 0.08, 0.21 and 0.18 respectively), PTD (OR 0.52, 0.68 and 0.56 respectively) and LBW(0.37, 0.61 and 0.52 respectively). CONCLUSION: An improvement in birth outcomes is likely associated with the increased coverage of triple antiretroviral treatment for pregnant women. And untreated HIV infected women and women who do not seek antenatal care should be considered most at risk for poor birth outcomes. |
format | Online Article Text |
id | pubmed-4750240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47502402016-02-12 Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa Moodley, Theron Moodley, Dhayendre Sebitloane, Motshedisi Maharaj, Niren Sartorius, Benn BMC Pregnancy Childbirth Research Article BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large regional hospital in South Africa during July-December 2011 and January-June 2014 with an aim to determine an association between pregnancy outcomes and the ARV treatment guidelines implemented during those specific periods. During 2011, women received either Zidovudine/sd Nevirapine or Stavudine/Lamivudine/Nevirapine if CD4+ count was < 350 cells/ml. During 2014, all HIV positive pregnant women were eligible for a fixed dose combination (FDC) of triple ARVs (Tenofovir/Emtracitabine/Efavirenz). RESULTS: In 2011, 622 (35.9 %) of 1732 HIV positive pregnant women received triple antiretrovirals (D4T/3TC/NVP) and in 2014, 2104 (94.8 %) of 2219 HIV positive pregnant women received the fixed dose combination (TDF/FTC/EFV). We observed a reduction in the proportion of unregistered pregnancies, caesarean delivery rate, still birth rate, very low birth weight rate, and very premature delivery rate in 2014. In a bivariate analysis of all 9,847 deliveries, unregistered pregnancies (2.2 %) and HIV infection (37.8 %) remained significant risk factors for SB(OR 6.36 and 1.43 respectively), PTD(OR 4.23 and 1.26 respectively),LBW (OR 4.07 and 1.26 respectively) and SGA(OR 2.17 and 1.151 respectively). In a multivariable analysis of HIV positive women only, having received AZT/NVP or D4T/3TC/NVP or EFV/TDF/FTC as opposed to not receiving any ARV was significantly associated with reduced odds of a SB (OR 0.08, 0.21 and 0.18 respectively), PTD (OR 0.52, 0.68 and 0.56 respectively) and LBW(0.37, 0.61 and 0.52 respectively). CONCLUSION: An improvement in birth outcomes is likely associated with the increased coverage of triple antiretroviral treatment for pregnant women. And untreated HIV infected women and women who do not seek antenatal care should be considered most at risk for poor birth outcomes. BioMed Central 2016-02-11 /pmc/articles/PMC4750240/ /pubmed/26867536 http://dx.doi.org/10.1186/s12884-016-0821-3 Text en © Moodley et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Moodley, Theron Moodley, Dhayendre Sebitloane, Motshedisi Maharaj, Niren Sartorius, Benn Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title_full | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title_fullStr | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title_full_unstemmed | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title_short | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa |
title_sort | improved pregnancy outcomes with increasing antiretroviral coverage in south africa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750240/ https://www.ncbi.nlm.nih.gov/pubmed/26867536 http://dx.doi.org/10.1186/s12884-016-0821-3 |
work_keys_str_mv | AT moodleytheron improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica AT moodleydhayendre improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica AT sebitloanemotshedisi improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica AT maharajniren improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica AT sartoriusbenn improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica |